A phase II multicenter, controlled, double-blind study using immunoprophylaxis in the primary prevention of allergic disease
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Allergy immunotherapy (Primary)
- Indications Allergic rhinitis; Asthma
- Focus Therapeutic Use
- Acronyms GPAC
- 01 May 2017 Biomarkers information updated
- 07 Mar 2012 Actual patient number is 50 according to ClinicalTrials.gov.
- 07 Mar 2012 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.